$146 Million is the total value of Nan Fung Group Holdings Ltd's 40 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 22.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $31,017,000 | -17.1% | 635,978 | -17.3% | 21.30% | +20.1% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $28,552,000 | -4.1% | 225,688 | -3.9% | 19.61% | +38.9% |
| ILMN | Sell | ILLUMINA INC | $21,975,000 | -51.5% | 119,196 | -8.1% | 15.09% | -29.7% |
| EXSCIENTIA PLCads | $8,387,000 | -24.4% | 770,200 | 0.0% | 5.76% | +9.5% | ||
| SGEN | SEAGEN INC | $8,333,000 | +22.8% | 47,096 | 0.0% | 5.72% | +77.9% | |
| SOMALOGIC INC | $7,668,000 | -43.6% | 1,696,558 | 0.0% | 5.27% | -18.4% | ||
| RANI THERAPEUTICS HLDGS INC | $5,099,000 | -23.5% | 493,584 | 0.0% | 3.50% | +10.8% | ||
| XENE | Sell | XENON PHARMACEUTICALS INC | $3,479,000 | -42.5% | 114,380 | -42.2% | 2.39% | -16.7% |
| REPL | Buy | REPLIMUNE GROUP INC | $2,713,000 | +114.5% | 155,199 | +108.4% | 1.86% | +210.5% |
| SNOW | New | SNOWFLAKE INCcl a | $2,671,000 | – | 19,210 | +100.0% | 1.84% | – |
| INCY | INCYTE CORP | $2,613,000 | -4.3% | 34,391 | 0.0% | 1.80% | +38.6% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $2,381,000 | -25.5% | 1,166,952 | 0.0% | 1.64% | +7.8% | |
| ISEE | New | IVERIC BIO INC | $2,285,000 | – | 237,484 | +100.0% | 1.57% | – |
| EAR | EARGO INC | $2,171,000 | -85.8% | 2,886,724 | 0.0% | 1.49% | -79.4% | |
| ENTRADA THERAPEUTICS INC | $2,114,000 | +29.7% | 173,582 | 0.0% | 1.45% | +87.8% | ||
| BGNE | BEIGENE LTDsponsored adr | $1,946,000 | -14.2% | 12,022 | 0.0% | 1.34% | +24.4% | |
| OTIC | OTONOMY INC | $1,770,000 | -13.4% | 851,080 | 0.0% | 1.22% | +25.5% | |
| EXEL | EXELIXIS INC | $1,337,000 | -8.1% | 64,200 | 0.0% | 0.92% | +33.0% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $946,000 | +60.3% | 370,950 | 0.0% | 0.65% | +132.1% | |
| CCXI | CHEMOCENTRYX INC | $888,000 | -1.1% | 35,830 | 0.0% | 0.61% | +43.2% | |
| GRTX | GALERA THERAPEUTICS INC | $797,000 | -45.4% | 613,223 | 0.0% | 0.55% | -21.0% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $775,000 | -33.2% | 78,720 | 0.0% | 0.53% | -3.3% | |
| PACB | PACIFIC BIOSCIENCES CALIF IN | $640,000 | -51.4% | 144,840 | 0.0% | 0.44% | -29.6% | |
| STSA | SATSUMA PHARMACEUTICALS INC | $592,000 | +9.0% | 142,900 | 0.0% | 0.41% | +57.8% | |
| 2SEVENTY BIO INC | $532,000 | -22.6% | 40,273 | 0.0% | 0.36% | +12.0% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $507,000 | +7.6% | 6,115 | 0.0% | 0.35% | +56.1% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $422,000 | -41.9% | 29,984 | 0.0% | 0.29% | -15.7% | |
| ARGX | ARGENX SEsponsored adr | $421,000 | +20.3% | 1,110 | 0.0% | 0.29% | +74.1% | |
| ASND | ASCENDIS PHARMA A/Ssponsored adr | $387,000 | -20.9% | 4,168 | 0.0% | 0.27% | +14.7% | |
| New | HASHICORP INC | $383,000 | – | 13,001 | +100.0% | 0.26% | – | |
| ALXO | ALX ONCOLOGY HLDGS INC | $339,000 | -52.2% | 41,950 | 0.0% | 0.23% | -30.7% | |
| SRPT | SAREPTA THERAPEUTICS INC | $294,000 | -3.9% | 3,917 | 0.0% | 0.20% | +39.3% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $251,000 | -7.4% | 8,265 | 0.0% | 0.17% | +33.3% | |
| AFMD | AFFIMED N V | $225,000 | -36.6% | 81,172 | 0.0% | 0.16% | -7.7% | |
| FGEN | FIBROGEN INC | $156,000 | -11.9% | 14,756 | 0.0% | 0.11% | +27.4% | |
| KOD | KODIAK SCIENCES INC | $150,000 | -0.7% | 19,622 | 0.0% | 0.10% | +43.1% | |
| ABCL | ABCELLERA BIOLOGICS INC | $133,000 | +9.0% | 12,521 | 0.0% | 0.09% | +56.9% | |
| SYBX | SYNLOGIC INC | $79,000 | -52.1% | 68,634 | 0.0% | 0.05% | -30.8% | |
| CERS | CERUS CORP | $75,000 | -3.8% | 14,172 | 0.0% | 0.05% | +40.5% | |
| TCRR | TCR2 THERAPEUTICS INC | $56,000 | +5.7% | 19,335 | 0.0% | 0.04% | +52.0% | |
| NVTA | Sell | INVITAE CORP | $28,000 | -97.7% | 11,337 | -92.7% | 0.02% | -96.8% |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -11,629 | -100.0% | -0.05% | – |
| DAWN | Exit | DAY ONE BIOPHARMACEUTICALS I | $0 | – | -11,445 | -100.0% | -0.05% | – |
| RUBY | Exit | RUBIUS THERAPEUTICS INC | $0 | – | -56,768 | -100.0% | -0.15% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -17,464 | -100.0% | -0.58% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -52,979 | -100.0% | -0.80% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -54,903 | -100.0% | -1.49% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -210,563 | -100.0% | -2.57% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.